Tengfei Creation Center,55 Jiangjun Avenue, Jiangning District,Nanjing admin@sinochem-nanjing.com 3389378665@qq.com
Follow us:

4-Bromo-7-Azainazole, 4-Bromopyrazolo[3,4-B]Pyridine

    • Product Name 4-Bromo-7-Azainazole, 4-Bromopyrazolo[3,4-B]Pyridine
    • Alias 4-Bromo-7-azaisoinidazole
    • Einecs 841-498-9
    • Mininmum Order 1 g
    • Factory Site Tengfei Creation Center,55 Jiangjun Avenue, Jiangning District,Nanjing
    • Price Inquiry admin@sinochem-nanjing.com
    • Manufacturer Sinochem Nanjing Corporation
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    357702

    Chemical Name 4-Bromo-7-Azainazole
    Alternative Name 4-Bromopyrazolo[3,4-b]pyridine
    Molecular Formula C6H3BrN3
    Molecular Weight 198.01 g/mol
    Cas Number 877399-50-1
    Appearance White to off-white solid
    Purity Typically ≥ 97%
    Solubility Soluble in DMSO, DMF; sparingly soluble in water
    Boiling Point Decomposes before boiling
    Smiles Brc1cnn2ccccn12
    Storage Conditions Store at 2-8°C, keep tightly closed, protect from light
    Synonyms 4-Bromo-pyrazolo[3,4-b]pyridine; 4-Bromo-7-azainazole
    Application Pharmaceutical intermediate, research chemical

    As an accredited 4-Bromo-7-Azainazole, 4-Bromopyrazolo[3,4-B]Pyridine factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing
    Shipping
    Storage
    Application of 4-Bromo-7-Azainazole, 4-Bromopyrazolo[3,4-B]Pyridine

    Applications of 4-Bromo-7-Azainazole, 4-Bromopyrazolo[3,4-B]Pyridine in Industrial Manufacturing

    Our proprietary synthesis of 4-Bromo-7-azainazole supports high-purity supply for regulated downstream sectors. As the original manufacturer, we ensure precise batch consistency meeting stringent industry requirements through advanced process controls and targeted impurity management. Below are our key industrial application tracks and their technical standards.

    1. Pharmaceutical Intermediates for Kinase Inhibitor Synthesis

    This compound serves as a critical heterocyclic intermediate in the targeted synthesis of kinase inhibitors. Process chemists incorporate it at the core structure-building stage, exploiting its nitrogen framework for selectivity in scaffold elaboration. It enables further functionalization via Suzuki or Buchwald-Hartwig coupling, forming the central aromatic ring system required in pyridine-based anticancer or anti-inflammatory drug candidates. Downstream, traceability and impurity profiling align with ICH Q7A requirements for bulk API production, while in-process controls (IPCs) are mandatory during scale-up to address residual bromide levels.

    Industry compliance standards

    • ICH Q7A Good Manufacturing Practice Guidelines
    • USP General Chapter <797> for hazardous drug compounding (for pilot-scale pathways)
    • EMA/CHMP/QWP/245074/2015 for control of nitrosamine impurities
    • 21 CFR Part 211 (FDA – cGMP for Finished Pharmaceuticals, as relevant for intermediates)

    Typical usage ratio

    • Applied at 0.18–0.40 molar equivalents relative to final API backbone, based on required substitution pattern. Ratio may be tailored to accommodate route specificity and step yield.

    Downstream process integration

    • Introduced during the key coupling stage in heterocycle formation, generally in anhydrous polar aprotic solvents followed by selective catalyst-driven transformations; purified pre-final deprotection/hydrolysis step.

    Final product types

    • Small-molecule kinase inhibitors (oncology, immunology pipelines)
    • Clinical-stage lead compounds for central nervous system drug programs
    • Commercial and pre-commercial drug substances (NCEs)
    • Active pharmaceutical ingredient (API) synthons

    2. Agrochemical Active Ingredient Precursor

    Agrochemical formulators source this intermediate for the synthesis of novel heterocyclic herbicides and fungicides. Its electron-rich nitrogen system supports combinatorial chemistry workflows aimed at enhancing biological mode-of-action specificity. Industrial protocols often require strict isolation at intermediate purification before downstream halogen exchange or amide bond functionalization, as per OECD and ISO requirements for agrochemical manufacturing. Quality control focuses on minimizing residual bromide and assessing isomeric purity during multi-hectare batch campaigns.

    Industry compliance standards

    • OECD Principles of Good Laboratory Practice (GLP) for active substance synthesis
    • ISO 9001:2015 for process traceability
    • REACH Regulation (EC) No 1907/2006 registration for raw material imports in Europe
    • FAO/WHO Food and Agriculture Organization Pesticide Specifications (when used in final product)

    Typical usage ratio

    • Utilized at 0.22–0.35 molar equivalents relative to the final agrochemical backbone, adjusted to optimize desired substitution patterns in downstream libraries.

    Downstream process integration

    • Fed into the synthesis after initial base ring construction, typically involved in Pd-catalyzed bond formation and subsequent chlorination steps; isolated prior to formulation blending and microencapsulation processes.

    Final product types

    • Pyrazolopyridine-based fungicides
    • Systemic herbicide active ingredients
    • Combination crop protection products
    • Biological screening libraries for new agro actives

    3. Materials Science – OLED and Organic Electronics Precursors

    In the advanced materials sector, device engineers deploy this raw material as a precursor to nitrogen-doped polyaromatic electron transport layers. Its distinct bromo-substituted azainazole motif supports precise positional derivatization, fundamental for achieving reproducible charge mobility and tuning energy band gaps in organic light-emitting diodes (OLEDs). Downstream, integration requires rigorous anhydrous processing and exclusion of transition metal contaminants per IEC and IPC substrates guidelines. Batch release involves dual certificate-of-analysis issuance for both purity and heavy metal content, specifically for optoelectronic grade intermediates.

    Industry compliance standards

    • IEC 60601-1 standards for electronic device safety (downstream application)
    • IPC-4101D for base materials in printed circuits
    • RoHS 2011/65/EU compliance for restricted substances
    • ISO 14001 for environmental management of electronic chemical production

    Typical usage ratio

    • Range 0.09–0.22 molar equivalents in polymer matrix precursor feedstocks; proportion controlled based on target thin-film conductivity and device layer thickness optimization.

    Downstream process integration

    • Used during monomer functionalization prior to polycondensation for the synthesis of electron transport or hole-blocking layers; later processed into thin films by spin-coating or vapor deposition on patterned ITO-glass substrates.

    Final product types

    • Organic light-emitting diode (OLED) emitters
    • Electron-transport polymers
    • Organic field-effect transistor (OFET) components
    • Flexible display substrates

    4. API Building Block for CNS Active Compound Development

    Medicinal chemistry teams employ this advanced intermediate as a scaffold for CNS-targeted drug development, focusing on regulation of neurotransmitter receptor systems. High-purity batches enable consistent SAR (structure–activity relationship) exploration, while low-metal specification ensures accurate downstream electrophilic and cross-coupling derivatizations. Manufacturing meets USP and EP monograph requirements for pyrazolopyridine structures, and routine lot tests confirm absence of genotoxic and elemental impurities per ICH M7 and Q3D guidelines. GMP change control maintains alignment with validated process routes, facilitating downstream IND and NDA filings.

    Industry compliance standards

    • USP and Ph. Eur. monographs for pyrazolopyridine-type intermediates
    • ICH Q3A/Q3D guidelines for impurities and elemental analysis
    • FDA 21 CFR 210/211 for quality systems
    • EU GMP EudraLex Volume 4, Part II for APIs (as starting material)

    Typical usage ratio

    • Normally integrated at 0.10–0.16 molar equivalents relative to the primary CNS drug backbone. Ratio calibrated by project stage and drug substance design.

    Downstream process integration

    • Introduced into core structure-building step, typically at late-stage diversification in CNS agent synthesis; purified prior to final salt formation or chiral resolution steps for GMP pilot lots.

    Final product types

    • NCEs for central nervous system (CNS) disorders
    • Clinical trial API batches (depression, anxiety, neurodegeneration programs)
    • Marketed branded CNS drugs (after multi-step API synthesis)
    • Regulatory submission samples (IND, NDA studies)

    5. Custom Synthesis for Chemical Research Reference Libraries

    Contract research organizations (CROs) and industrial R&D labs utilize this compound in the rapid assembly of chemical reference libraries. Its bromo-azainazole motif serves as a privileged structure for testing new ligand designs or complex heterocycle modifications. Project delivery often requires batch customization to research-grade analytical standards with certificates of analysis (COA) indicating spectroscopic purity and residual solvent content well below ICH Q3C recommendations. Traceable batch documentation and safety data sheets accompany each shipment to facilitate immediate research use without repurification.

    Industry compliance standards

    • ISO/IEC 17025 for analytical testing of supplied reference samples
    • ICH Q3C for residual solvent limits in research chemicals
    • Dow Europe Technical Agreement (for multinational research supply)
    • Sigma-Aldrich Laboratory Research Chemical Grade protocols

    Typical usage ratio

    • Utilized at 1.0–5.0 mg per reference compound synthesis, or up to 0.05 equivalents in small-scale parallel library generation; ratio specified by compound set design for lead exploration or benchmarking studies.

    Downstream process integration

    • Employed as a key building block in microwell synthesis, click-reaction setups, or late-stage diversification of small-molecule libraries; analysis follows with HPLC, NMR, and LC-MS verification per project specification.

    Final product types

    • Analytical reference compounds
    • Combinatorial chemistry lead panels
    • Biological screening standards
    • Research and development pilot sample sets

    6. Specialty Dye Intermediate for Diagnostic Reagents

    Diagnostic manufacturers source this pyrazolo[3,4-b]pyridine derivative as a precursor in the manufacture of specialty colorimetric or fluorimetric dyes. Its heterocyclic structure allows precise introduction of chromophore groups in photoactive labels for ELISA, immunoassay, or molecular diagnostic platforms. Downstream requirements mandate compliance with ISO 13485 quality management for medical device components, and raw materials must pass Release for Use (RFU) after QC determination of organic and heavy metal impurities. Lot traceability from origin through purification is maintained for full regulatory document compatibility in clinical reagent manufacturing.

    Industry compliance standards

    • ISO 13485 Medical Devices – Quality Management Systems for dye precursors
    • EN ISO 10993-18 for chemical characterization in medical device raw materials
    • CLSI guidelines for laboratory reagent quality
    • FDA 21 CFR Part 820 for medical device manufacturing controls (applicable in US market)

    Typical usage ratio

    • Introduced at 0.03–0.09 equivalents in dye coupling reactions; exact ratio defined by the spectral density and emission calibration requirements of the final diagnostic product.

    Downstream process integration

    • Engaged during chromophore installation step; subsequently incorporated into protein or nucleic acid conjugates through proprietary labeling reactions before formulation and lyophilization of final diagnostic kits.

    Final product types

    • Colorimetric diagnostic reagents for medical assays
    • Fluorescent tracer dyes for immunoassays
    • In vitro diagnostic (IVD) marker kits
    • High-sensitivity ELISA labels
    Free Quote

    Competitive 4-Bromo-7-Azainazole, 4-Bromopyrazolo[3,4-B]Pyridine prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.

    We will respond to you as soon as possible.

    Tel: +8615371019725

    Email: admin@sinochem-nanjing.com

    Get Free Quote of Sinochem Nanjing Corporation

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    Spotlight on 4-Bromo-7-Azainazole: Brave New Ground for Modern Synthesis

    Redefining Lab Possibilities with 4-Bromopyrazolo[3,4-B]Pyridine

    Researchers spend countless hours sorting through reagent catalogs and chemical building blocks, looking for just the right piece for the puzzle at hand. Every so often, a reagent stands out — either for its flexibility, its well-earned reputation, or for helping chemists break through bottlenecks they've encountered before. 4-Bromo-7-azainazole, known by its system name 4-bromopyrazolo[3,4-b]pyridine, often draws attention for exactly those reasons.

    Sitting at the intersection of convenience and scientific innovation, this compound brings a lot to the workbench. In the ever-expanding toolbox available to synthetic chemists, it manages to carve out a unique niche. Its molecular structure, featuring the fused pyrazolopyridine ring and bromine at the 4-position, opens doors for coupling reactions that other scaffolds can’t quite match. The molecular formula, C6H3BrN4, captures the idea of a size-efficient frame with untapped potential for derivatization.

    How 4-Bromo-7-azainazole Moves Science Forward

    Experienced synthetic chemists know that the subtle differences between similar heterocycles can spell success or failure in the lab. In my own years in research, I’ve run into the limits of purine, imidazole, and other nitrogen-rich rings. The pyrazolopyridine backbone present in 4-bromo-7-azainazole stands out for several reasons. The fused system combines aromatic stability with reactivity in cross-coupling, delivering options where more conventional heterocycles disappoint.

    What truly separates this compound is its performance in Suzuki, Negishi, or Sonogashira couplings. The bromine at the 4-position acts as a solid leaving group, which makes catalytic transformations hum along with minimal byproducts. In comparison, common halogenated pyridines often react sluggishly, or stall mid-way, clogging up purification columns and wasting valuable time. Every synthetic chemist who has ever watched a TLC plate and sighed as a starting material lingered longer than desired can understand the pain of uncooperative substrates. 4-Bromo-7-azainazole picks up the slack.

    The Real-World Impact: From Medicinal Chemistry to Materials Science

    The structure of 4-bromopyrazolo[3,4-b]pyridine paves the way for creativity in pharma, agrochemicals, and advanced materials. Drug discovery teams searching for kinase inhibitors or receptor modulators have relied increasingly on pyrazolopyridine scaffolds for their unique binding advantages. With bromine standing ready for functionalization, companies can quickly generate small libraries of analogs in SAR work. I have discussed project bottlenecks with teams who tell me they trimmed months from their lead optimization cycles by swapping out less reactive heterocycles for pyrazolopyridine-based chemistry.

    Some research outfits probing the frontiers of optoelectronics or dye chemistry lean on the same molecular backbone to create vivid, persistent colors or tweak electronic properties. The key is the blend of aromaticity and nitrogen density, bringing tunable dipole moments and hydrogen bonding patterns missing from simpler rings. Materials scientists want to play with electron flow and tuning bandgaps without endless synthetic dead ends; 4-bromo-7-azainazole meets those labs more than halfway.

    No-Nonsense Handling and Specifications: Addressing the Lab’s Daily Grind

    The catalog version of 4-bromo-7-azainazole typically appears as a pale to off-white solid. While chemical appearance rarely tells the whole story, in this case, it’s a helpful sign for purity. Labs chasing clean spectra and reliable characterization need to watch for color impurities; the near-white tone gives a decent first check. Well-stocked suppliers usually offer the compound in gram to kilogram quantities, letting both bench-scale and process teams get what they need.

    Solubility and stability both matter. This bromo-heterocycle dissolves well enough in popular polar aprotic solvents like DMF, DMSO, or acetonitrile, and usually survives storage under argon or nitrogen, away from strong light and humidity. Run-of-the-mill halides can be fussy about hydrolysis or decomposition, but I have seen unopened containers of 4-bromo-7-azainazole stay solid and stable for months with only basic precautions. This reliability keeps reordering and expense worries to a minimum and reduces time lost to rechecking expired reagents.

    How It Stands Apart from Lookalike Reagents

    Plenty of bromo-substituted heterocycles float around the market. Bromopyridines, bromopyrazoles, and their cousins all have their moments, but 4-bromo-7-azainazole breaks away for a few reasons. Its rigid structure, with two rings locked together, gives it a three-dimensional shape that fits into some active sites where simpler heterocycles flop. Drug chemists don’t always get excited about the nth version of a halogenated ring unless it offers a molecular “hook” for interacting with enzymes or receptors; this scaffold brings those hooks, both with nitrogen atoms and ring geometry.

    In testing, I’ve found that 4-bromo-7-azainazole reacts more predictably in Pd-catalyzed couplings compared to both pyridines and other pyrazolopyridines missing the 4-bromo handle. The regioselectivity offered by the fused ring system and the bromo substitution makes downstream modifications less painful. Working through columns, I noticed cleaner separations and fewer side-product headaches. Colleagues have echoed similar experiences, especially in discovery chemistry, where work-up time can make or break a project.

    Supporting Reproducibility: Reliability in Scale-Up

    Once a promising hit pops up in a research screen, process chemists think ahead to how easily a scaffold converts into useful products at scale. Some library compounds turn into nightmares in larger glassware, refusing to dissolve or throwing off inconsistent yields. 4-bromo-7-azainazole usually makes this jump smoother, owing to its chemical sturdiness and consistent handling profile.

    Analytical teams appreciate that this compound lends itself well to clean NMR and mass spectra, with the bromine atom providing a clear signature. From thin-layer chromatography up to preparative HPLC, tracking progress and side products doesn’t turn into a guessing game. Scale-up teams can focus on reaction optimization and final formulation, with fewer distractions from erratic impurity peaks. That kind of reliability pays dividends all along the R&D chain, from the initial trial to production lots.

    Emphasizing Safety and Responsible Sourcing

    Every compound carries responsibilities for safe handling, mindful use, and ethical sourcing. 4-bromo-7-azainazole is no exception, and veteran chemists remind new team members to keep lab basics in mind: glove up, avoid direct contact, and control exposure during weighing and handling. I’ve seen researchers work most smoothly when they lay out a steady, practiced approach — clean bench, careful transfer, and a sharp eye on reaction monitoring.

    Ethical sourcing sometimes flies under the radar in routine procurement, but transparency helps companies and research groups avoid supply chain headaches. Trustworthy suppliers with solid reputations and documentation support both reproducibility and sustainable growth. In one project I joined, an unexpected impurity from a low-cost supplier derailed weeks of work. Since then, using a vetted supplier, especially for a critical building block like this, became a non-negotiable step.

    Tapping the Compound’s Adaptability

    The magic of 4-bromopyrazolo[3,4-b]pyridine comes alive most clearly in the hands of creative chemists open to exploring structure–activity relationships (SAR) and new reaction types. As heavier, larger-scale moves emerge in pharmaceutical and materials science pipelines, flexibility starts to separate theoretical breakthroughs from real solutions. This compound has proven itself across medicinal chemistry campaigns and even in the exploratory hands of academic labs seeking new spin-offs in ligand or probe development.

    Some teams have branched out beyond standard C–C coupling, using the bromo group to build C–N or C–O bonds, or leveraging halogen–metal exchange to make Grignard-type or organozinc intermediates. These avenues unlock more than just catalog diversity; they speed up routes from concept to synthesis, and sometimes open brand-new classes of target molecules. My own experience with late-stage functionalization taught me that introducing substitutions at the right moment made all the difference in yield and downstream versatility. 4-bromo-7-azainazole grants that level of control.

    Common Questions on Practical Use

    Some researchers new to pyrazolopyridines worry about issues like sensitivity to air or moisture, odd reactivity, or purification hassles. The truth is more encouraging. This compound resists oxidation, shrugs off modest humidity spikes, and rarely hydrolyzes in standard glassware. Running reactions under nitrogen produces good, reliable outcomes but the material remains forgiving enough for bench-scale trials. After several grams-to-decagram syntheses, columns stayed clean and yields matched expectations. If purification does pose any challenge, I recommend combinations of silica and reverse-phase chromatography, based on repeated positive outcomes in the field.

    Those after high-throughput synthesis or automated workflows need reagents that behave predictably across dozens of runs. 4-bromo-7-azainazole keeps the human element in focus: the protocols you use on Monday remain valid the next week, and batch variance stays low. Automated liquid handlers, parallel reactors, and purification robots often throw up unexpected quirks with more finicky scaffolds, but with this compound, reliability keeps throughput high and troubleshooting to a minimum.

    Beyond Chemistry: Catalyzing Ideas Across Disciplines

    Scientific progress feeds on collaboration. The reach of 4-bromopyrazolo[3,4-b]pyridine extends outside the walls of pure organic synthesis. Biologists use derivatives in fluorescent labeling. Physical chemists probe unusual π-electron distributions. Computational teams build models to predict binding and electronic properties, drawing on experimental data made possible by reliable, well-behaved starting materials.

    Working with multidisciplinary teams, I’ve watched the compound move from bench to computer screen to assay, without gaps caused by stubborn reagents or inconsistent lots. That seamless flow matters—accelerating innovation and freeing up talented thinkers for deeper work, instead of being bogged down in avoidable troubleshooting cycles.

    Promising Solutions and Ongoing Developments

    Innovation doesn’t happen in a vacuum. Scientists and suppliers continue to improve sourcing, purity, and documentation for key building blocks like 4-bromo-7-azainazole. Ongoing research is delivering new purification techniques and scalable syntheses, removing both bottlenecks and cost hurdles. Teams focused on “green chemistry” have already begun testing solvent swaps and milder conditions, reducing environmental impact while preserving the compound’s utility.

    Communication across the research, procurement, and process teams plays a central role. Bringing together feedback from the lab bench and pilot plant allows producers to fine-tune product grades, packaging, and shipping safety. Instead of one-size-fits-all, this approach encourages continual adaptation, keeping the needs of discovery scientists, development chemists, and production engineers front and center.

    Why Attention to Detail Matters: Lessons from the Field

    Having spent years watching innovations struggle or shine based on reagent quality, I keep returning to the value of attention to detail. From first opening a package of 4-bromo-7-azainazole, to capping the bottle after a successful coupling run, small steps reinforce scientific integrity. Checking certificates of analysis, logging lot numbers, and revisiting storage protocols guard against surprises days or weeks down the line.

    I remember one heated group meeting where an early-phase medicinal chemist compared half a dozen routes for making a high-value kinase inhibitor fragment. Her process only clicked once she landed on 4-bromo-7-azainazole — yields doubled, and a sticky purification turned into a single pass of clean fractions. The group shifted focus, hit milestones on time, and avoided the frustration of chasing down ghost peaks and byproducts. Experiences like that justify careful, informed product selection for each step in the synthesis.

    The Place of 4-Bromopyrazolo[3,4-b]pyridine in the Modern Toolbox

    4-bromo-7-azainazole’s rise isn’t the story of a hype-driven chemical fad. It comes from real results in labs and a proven ability to adapt to complex demands. Researchers who hunger for responsive, predictable performance in small-scale discovery or full-scale process find this compound earns its place alongside staples like aryl halides and classic heterocycles.

    Chemistry changes day by day. New targets, new classes of molecular probes, and ever tighter project timelines make the stakes higher for product selection. Choosing 4-bromo-7-azainazole over other bromo-heterocycles often means cuts in cycle time, increases in output, and a decrease in troubleshooting — benefits that trickle down from individual researchers to project teams and organizations.

    Looking Forward: Next Frontiers for an Essential Building Block

    The story of 4-bromopyrazolo[3,4-b]pyridine continues to unfold, from new applications in small molecule medicine to semiconductor targets where nitrogen-rich scaffolds shift device performance. I see more teams bridging biology and materials science, relying on robust chemical staples to try riskier ideas and stretch research boundaries. Adoption at this level often boils down to trust — both in the compound itself and in the infrastructure that delivers it reliably worldwide. This foundation allows innovators to focus less on technical headaches, and more on genuine discovery.

    From bench-top to bulk, the track record speaks for itself. As demand for fresh molecular architectures keeps growing and global standards for documentation and reproducibility rise, the unique advantages of 4-bromo-7-azainazole keep it relevant, timely, and in demand. Over years of hands-on synthesis work, these are the qualities that set standout building blocks apart from the crowd — and they’re why promising research keeps finding new directions, powered by familiar names on reagent shelves.